Skip to main content
Premium Trial:

Request an Annual Quote

Quanterix Raises $49.7 in Stock Offering

NEW YORK (GenomeWeb) – Quanterix said after the close of the market today that it raised $49.7 million last week via issue of 2.2 million shares of common stock.

The company sold the shares at an average price of $22.73 per share under a $50 million at-the-market equity facility it filed as part of a shelf registration statement with the US Securities and Exchange Commission in March 2019. It said that it will use the proceeds to fund commercial expansion, particularly in China, to accelerate research and development aimed at boosting its instrument sensitivity, and for new product development and acquisitions.

Quanterix also said that it planned to release its Simoa HD-X analyzer on Wednesday at the BIO International Convention in Philadelphia. The HD-X will replace the company's original HD-1 analyzer.

Quanterix is currently taking orders for the HD-X and plans to begin shipping instruments in Q4 2019.

The Scan

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.

Meta AI Computer Model Rapidly Predicts Hundreds of Millions of Metagenomic Proteins

Meta AI researchers describe in Science a new large language model that can predict the structures of millions of metagenomic proteins.

Hutch Team Develops Platform for Assessing Impact of SARS-CoV-2 Spike Mutations

The approach described in Cell relies on lentiviral pseudotyping for mutational scanning, which the researchers applied to the SARS-CoV-2 spike protein.

Potential New Therapeutic Target for Rheumatoid Arthritis Discovered

Researchers report in the American Journal of Human Genetics that SNPs implicated in rheumatoid arthritis often regulate the expression of the inflammation-related SPRED2 gene.